Known targets — ChEMBL curated mechanism
ABL1BRAFDDR2EPHA2FGFR1FGFR2FLT1FLT4FRKKDRKITMAPK11NTRK1PDGFRAPDGFRBRAF1RETTEK
The experimentally established mechanism targets of Regorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.98 |
| ▸ | BRAF known ✓ | P15056 | 7/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.98 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.98 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.98 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.98 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.98 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.98 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 0.98 |
| ▸ | MAPK11 known ✓ | Q15759 | 2/20 | 0.98 |
| ▸ | DDR2 known ✓ | Q16832 | 2/20 | 0.98 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.82 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.82 |
| ▸ | FRK known ✓ | P42685 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regorafenib SCHEMBL29496390 | 1.00 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29349808 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29351376 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL432230 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2555101 | 0.98 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29555444 | 0.98 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2552684 | 0.96 | RAF1 (0.93) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL30433607 | 0.93 | RAF1 (0.89) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL5086313 | 0.92 | RAF1 (0.87) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL22627130 | 0.91 | RAF1 (0.85) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12059429-B2 | Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-08-13 | — | — | US | claimed |
| CN-112730660-B | Method for detecting p-aminophenol substances by UPLC-MS/MS | 上海博悦生物科技有限公司 | 2021-09-21 | — | — | CN | claimed |
| US-20200155594-A1 | HORNERIN: A NOVEL NON-VEGF MEDIATED ANGIOGENIC PROTEIN EXPRESSED IN BOTH HUMAN AND MOUSE ANGIOGENIC ENDOTHELIAL CELLS AND HUMAN PANCREATIC CANCER CELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-21 | — | — | US | claimed |
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | claimed |
| US-20260074009-A1 | METHODS FOR IDENTIFYING TREATMENT TARGETS BASED ON MULTIOMICS DATA | INST SYSTEMS BIOLOGY (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | BRYET US, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4574214-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4308573-B1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHROEDINGER INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12268666-B2 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | LOXO ONCOLOGY, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-101547903-A | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate | BAYER HEALTHCARE AG (DE) | 2009-09-30 | — | — | CN | disclosed |
| CN-101547903-A | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate | BAYER HEALTHCARE AG (DE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2097381-A1 | 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)]CARBAMOYL}AMINO)-3-FLUOROPHENOX]-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097381-A1 | 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)]CARBAMOYL}AMINO)-3-FLUOROPHENOX]-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097381-A1 | 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)]CARBAMOYL}AMINO)-3-FLUOROPHENOX]-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008043446-A1 | 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043446-A1 | 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043446-A1 | 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | MSN, CD47, CTTN | RAF1 3291/4885BRAF 1524/4885KDR 67/4885 |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | RAF1 127/4885BRAF 3/4885KDR 517/4885 |
| US-20260074009-A1 | METHODS FOR IDENTIFYING TREATMENT TARGETS BASED ON MULTIOMICS DATA | BRCA1, BCOR, L3MBTL4 | RAF1 3594/4885BRAF 3140/4885KDR 3145/4885 |
| US-20260049085-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | CCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MALT1 | RAF1 717/4885BRAF 771/4885KDR 2889/4885 |
| US-12268666-B2 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | API5, IL5, SRMS | RAF1 987/4885BRAF 375/4885KDR 3882/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | RAF1 33/4885BRAF 164/4885KDR 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.